Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

Biochemical Journal

Volumn 409, Issue 2, 2008, Pages 519-524

  Carson, Jeffrey D ^a   Van Aller, Glenn ^a   Lehr, Ruth ^a   Sinnamon, Robert H ^a   Kirkpatrick, Robert B ^a   Auger, Kurt R ^a   Dhanak, Dashyant ^a   Copeland, Robert A ^a   Gontarek, Richard R ^a   Tummino, Peter J ^a   Luo, Lusong ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Insulin receptor substrate 1 (IRS 1); Lipid kinase activation; Mutant activation; Oncogenic mutant; Phosphoinositide 3 kinase (PI3K )

Indexed keywords

CELLS; ENZYME ACTIVITY; INSULIN; MUTAGENESIS; REACTION KINETICS; TUMORS;

INSULIN RECEPTOR SUBSTRATE-1 (IRS-1); LIPID KINASE ACTIVATION; MUTANT ACTIVATION; ONCOGENIC MUTANT;

LIPIDS;

INSULIN RECEPTOR SUBSTRATE 1; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; 1 PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT, HUMAN; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, HUMAN; ADENOSINE TRIPHOSPHATE; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; RECOMBINANT PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; MUTATION; PRIORITY JOURNAL; CELL CULTURE; ENZYME ACTIVE SITE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; ONCOGENE; PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATE; ALLELES; CATALYTIC DOMAIN; ENZYME ACTIVATION; HUMANS; KINETICS; MUTATION; ONCOGENES; PHOSPHORYLATION; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 38749092231     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20070681     Document Type: Article

References (27)

1. Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C. M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J. et al. (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116, 2695-2706
2. Bader, A. G., Kang, S., Zhao, L. and Vogt, P. K. (2005) Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5, 921-929
3. Samuels, Y. and Ericson, K. (2006) Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18, 77-82
4. Morgensztern, D. and McLeod, H. L. (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16, 797-803
5. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. and Mills, G. B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004
6. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J. et al. (2004) High freguency of mutations of the PIK3CA gene in human cancers. Science 304, 554
7. Qiu, W., Schonleben, F., Li, X., Ho, D. J., Close, L. G., Manolidis, S., Bennett, B. P. and Su, G. H. (2006) PIK3CA mutations in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 1441-1446
8. Liu, Z. and Roberts, T. M. (2006) Human tumor mutants in the p110α subunit of PI3K. Cell Cycle 5, 675-677
9. Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C. and Brugge, J. S. (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65, 10992-11000
10. Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K. et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65, 4562-4567
11. Gallia, G. L., Rand, V., Siu, I. M., Eberhart, C. G., James, C. D., Marie, S. K., Oba-Shinjo, S. M., Carlotti, C. G., Caballero, O. L., Simpson, A. J. et al. (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol. Cancer Res. 4, 709-714
12. Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F. and Roberts, T. M. (2005) The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 102, 18443-18448
13. Kang, S., Bader, A. G. and Vogt, P. K. (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U.S.A. 102, 802-807
14. Drees, B. E., Weipert, A., Hudson, H., Ferguson, C. G., Chakravarty, L. and Prestwich, G. D. (2003) Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity. Comb. Chem. High Throughput Screen. 6, 321-330
15. Gymnopoulos, M., Elsliger, M. A. and Vogt, P. K. (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. U.S.A. 104, 5569-5574
16. Domin, J., Dhand, R. and Waterfield, M. D. (1996) Binding to the platelet-derived growth factor receptor transiently activates the p85α-p110α phosphoinositide 3-kinase complex in vivo. J. Biol. Chem. 271, 21614-21621
17. Backer, J. M., Myers, Jr, M. G., Sun, X. J., Chin, D. J., Shoelson, S. E., Miralpeix, M. and White, M. F. (1993) Association of IRS-1 with the insulin receptor and the phosphatidylinositol 3′-kinase. Formation of binary and ternary signaling complexes in intact cells. J. Biol. Chem. 268, 8204-8212
18. Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P. and Cantley, L. C. (1989) PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57, 167-175
19. Asano, T., Yao, Y., Shin, S., McCubrey, J., Abbruzzese, J. L. and Reddy, S. A. (2005) Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res. 65, 9164-9168
20. Yu, J., Wjasow, C. and Backer, J. M. (1998) Regulation of the p85/p110α phosphatidylinositol 3′-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. J. Biol. Chem. 273, 30199-30203
21. Wu, H., Yan, Y. and Backer, J. M. (2007) Regulation of class IA PI3Ks. Biochem. Soc. Trans. 35, 242-244
22. Shekar, S. C., Wu, H., Fu, Z., Yip, S. C., Nagajyothi Cahillg, S. M., Girvin, M. E. and Backer, J. M. (2005) Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J. Biol. Chem. 280, 27850-27855
23. Philp, A. J., Campbell, I. G., Leet, C., Vincan, E., Rockman, S. P., Whitehead, R. H., Thomas, R. J. and Phillips, W. A. (2001) The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426-7429
24. Jimenez, C., Jones, D. R., Rodriguez-Viciana, P., Gonzalez-Garcia, A., Leonardo, E., Wennstrom, S., von Kobbe, C., Toran, J. L., Borlado, L., Calvo, V. et al. (1998) Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. 17, 743-753
25. Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S. and Cantley, L. C. (1993) Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J. Biol. Chem. 268, 9478-9483
26. Rordorf-Nikolic, T., Van Horn, D. J., Chen, D., White, M. F. and Backer, J. M. (1995) Regulation of phosphatidylinositol 3′-kinase by tyrosyl phosphoproteins: full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J. Biol. Chem. 270, 3662-3666
27. Miled, N., Yan, Y., Hon, W. C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M. and Williams, R. L. (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239-242